Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — FY2021 Earnings Presentation
13 slides from Novonesis A/s Class B's earnings presentation, Feb 1, 2022
Slide 1: Conference call 12M 2021
Conference call 12M 2021 February 1, 2022
Slide 2: Forward Looking Statement
Disclaimer Forward Looking Statement This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: Highlights: Strong overall performance in 2021
Highlights Strong overall performance in 2021 Initial 2021 Latest 2021 Realized 2022 • Organic 12M sales growth y/y: 6% (Q4 y/y: 7%). outlook outlook 12M 2021 outlook • Double-digit growth in three out of five business areas demonstrates the strength of a well- Sales performance, organic % 2 to 6 5
Slide 4: Household Care
Household Care Solid performance in Emerging Markets and with Freshness; slight 2022 perspectives decline overall against tough COVID-19 impacted comparator • Growth driven by increased penetration in emerging • Organic 12M sales growth y/y: -1% (Q4 y/y: -3%). markets, Freshness, professional & medi
Slide 5: Food, Beverages & Human Health
Food, Beverages & Human Health Strong performance with all subareas growing double digits 2022 perspectives • Organic 12M sales growth y/y: 14% (Q4 y/y: 13%). • Growth in Food driven by market penetration, health- focused solutions as well as raw material optimization and • Food; mainly driven by ma
Slide 6: Bioenergy
Bioenergy Strong growth on the back of U.S. recovery 2022 perspectives • Organic 12M sales growth y/y: 11% (Q4 y/y: 10%). • Growth driven by continued recovery of U.S. ethanol production, innovation, capacity expansion in Latin • Strong 12M performance driven by recovery of U.S. ethanol America, and
Slide 7: Grain & Tech Processing
Grain & Tech Processing Strong performance based on growth across subareas 2022 perspectives • Organic 12M sales growth y/y: 13% (Q4 y/y: 15%). • Growth mainly from market penetration in vegetable oil processing and innovation. • Strong 12M performance primarily driven by innovation and higher end-m
Slide 8: Agriculture, Animal Health & Nutrition
Agriculture, Animal Health & Nutrition Flat despite negative base effect from BioAg one-off 2022 perspectives • Organic 12M sales growth y/y: 0% (Q4 y/y: 7%). • Innovation, new go-to-market model, and good market conditions are key enablers behind double-digit growth • Flat 12M sales development – g
Slide 9: Sustainability and non-financial targets
Sustainability and non-financial targets 8
Slide 10: Financial results
Financial results Strong overall performance in 2021, including 7% organic sales growth in Q4 • 12M organic sales growth y/y: 6%; DKK sales 7% y/y. • Gross margin strong at 57.7%; 170bps higher than last year driven by productivity improvements & efficiencies, sales leverage and to some extent M&A.
Slide 11: Financial outlook 2022
Financial outlook 2022 2022 outlook • Organic sales growth of 3% to 7% with sales in reported DKK around 3 percentage points higher. • EBIT margin of 25% to 26%. • ROIC incl. goodwill of 16% to 17%. • Free cash flow before acquisitions of DKK 1.7 to 2.1 billion. 2021 realized 2022 outlook Sales perf
Slide 12: Summary
Summary Strong overall performance in 2021; solid outlook for 2022; executing on strategic framework • Strong sales performance with double-digit growth in three out of five business areas. • Delivering on all key progress areas: - Partnerships - Innovations - Digital journey - Sustainability agenda
Slide 13: Slide 13